Technology ID
E-256-2013-0

Recombinant Pan-Lyssavirus for Use in Rabies and Broad-Lyssavirus Vaccination

Linked ID
TAB-2642
Inventors
Charles Rupprecht (CDC)
Ivan Kuzmin (CDC)
Xianfu Wu (CDC)
Lead Inventors
Xianfu Wu (CDC)
Co-Inventors
Charles Rupprecht (CDC)
Ivan Kuzmin (CDC)
Development Status
Pre-clinical
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • Pan-lyssavirus vaccines
  • Rabies surveillance and vaccination programs
CDC researchers have developed recombinant lyssaviruses that can be used for the development of an improved, broad-spectrum vaccine against several rabies genotypes. Lyssaviruses are single-stranded RNA viruses that cause rabies and rabies-like diseases in mammals. Currently, there are commercially available vaccines that are considered to be effective against infections from a single viral phylogroup; however, these vaccines confer little or no protection against viruses outside of the phylogroup. The present recombinants have glycoprotein-encoding genes from at least two different lyssaviruses and can be used as pan-lyssaviral vaccines to provide protection against infection by multiple lyssavirus phylogroups.
Competitive Advantages
  • Broad-spectrum vaccine potential
  • Pan-lyssavirus vaccination tools will be particularly beneficial in endemic and developing regions
  • Employs a presently commercialized vaccine backbone/platform, making this innovation easily adaptable for industrial R&D and subsequent large-scale production

Request More Info

Licensing Contact